Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1921-1928

  Villasenor Sierra A ^a,c   McShan, W M ^b   Salmi, D ^c   Kaplan, E L ^e,f   Johnson, D R ^e,f   Stevens, Dennis L ^c,d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c Boise VA Medical Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BACTERICIDAL ACTIVITY; CHEMOLUMINESCENCE; HUMAN; HUMAN CELL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CARRIER PROTEINS; CHEMILUMINESCENT MEASUREMENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNE SERA; MOLECULAR SEQUENCE DATA; OPSONIN PROTEINS; PHAGOCYTOSIS; SEQUENCE ANALYSIS, DNA; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0032708389     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315120     Document Type: Article

References (35)

1. 1. Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. Circulation 1985; 72:1155-62.
2. 2. Hosier DM, Craenen JN, Teske DW, Wheller JJ. Resurgence of acute rheumatic fever. Am J Dis Child 1987; 141:730-3.
3. 3. Stevens DL, Tanner MH, Winship J, et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med 1989; 321:1-7.
4. 4. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:374-82.
5. 5. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2:285-314.
6. 6. Dale JB, Beachey EH. Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 1985; 161:113-22.
7. 7. Denny FW, Perry WD, Wannamaker LW. Type-specific streptococcal antibody. J Clin Invest 1957; 36:1092-100.
8. 8. Lancefield RC. Persistence of type specific antibodies in man following infection with group A streptococci. J Exp Med 1959; 110:271-92.
9. 9. Lancefield RC. Current knowledge of the type specific antibodies in man following infection with group A streptococci. J Immunol 1962; 89:307-13.
10. 10. Lancefield RC, Perlman GE. Preparation and properties of type-specific M antigen isolated from a group A, type 1 hemolytic streptococcus. J Exp Med 1952; 96:71-82.
11. 11. Lancefield RC. The antigenic complex of Streptococcus haemolyticus. I. Demonstration of a type-specific substance in extracts of Streptococcus haemolyticus. J Exp Med 1928; 47:91-103.
12. 12. Harbaugh MP, Podbielski A, Hugl S, Cleary PP. Nucleotide substitutions and small-scale insertion produce size and antigenic variation in group A streptococcal M1 protein. Mol Microbiol 1993; 8:981-91.
13. 13. Robinson JH, Kehoe MA. Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today 1992; 13:362-7.
14. 14. Kalmar JR. Measurement of opsonic phagocytosis by human polymorphonuclear neutrophils. In: Clark VL, Bavoil PM, eds. Methods in enzymology. San Diego: Academic Press, 1994:108-19.
15. 15. Lancefield RC. Differentiation of group A streptococci with a common R antigen into three serological types with a special reference to the bactericidal test. J Exp Med 1957; 106:525-44.
16. 16. Beachey EH, Cunningham M. Type specific inhibition of preopsonization versus immunoprecipitation by streptococcal M proteins. Infect Immun 1973; 8:19-24.
17. 17. Allen RC. Evaluation of serum opsonic capacity by quantitating the initial chemiluminescent response from phagocytizing polymorphonuclear leukocytes. Infect Immun 1977; 15:828-33.
18. 18. Allen RC. Phagocyte leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol 1986; 133:449-93.
19. 19. Briheim G, Stendahl O, Dahlgren C. Intra-and extracellular events in luminol-dependent chemiluminescence of polymorphonuclear leucocytes. Infect Immun 1984; 45:1-5.
20. 20. Villasenor SA, Bryant AE, Stevens DL. Type-specific opsonophagocytosis of group A streptococcus using a rapid chemiluminescence assay. J Infect Dis 1999; 179:1293-6.
21. 21. Johnson DR, Kaplan EL. Indirect bactericidal test for measurement of antiM antibodies. In: Johnson DR, Kaplan EL, eds. Laboratory diagnosis of group A streptococcal infections. Geneva: World Health Organization, 1996:81-95.
22. 22. Stevens DL, Bryant AE, Huffman J, Thompson K, Allen RC. Analysis of circulating phagocyte activity measured by whole blood luminescence: correlations with clinical status. J Infect Dis 1994; 170:1463-72.
23. 23. Stollerman GH, Kantor FS, Gordon BD. Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. J Exp Med 1958; 108:475-91.
24. 24. Pitcher DG, Saunders NA, Owen RJ. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol 1989; 8:151-6.
25. 25. Whatmore AM, Kehoe MA. Horizontal gene transfer in the evolution of group A streptococcal emm-like genes: gene mosaics and variation in Vir regulons. Mol Microbiol 1994; 11:363-74.
26. 26. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996; 34:953-8.
27. 27. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25: 4876-2.
28. 28. Todd EW. Method of measuring increase or decrease of population of haemolytic streptococci in blood. Br J Exp Pathol 1927; 8:1-5.
29. 29. de Malmanche SA, Martin DR. Protective immunity to the group A streptococcus may be only strain specific. Med Microbiol Immunol 1994; 183: 299-306.
30. 30. Jones KF, Hollingshead SK, Scott JR, Fischetti VA. Spontaneous M6 protein size mutants of group A streptococci display variation in anligenic and opsonogenic epitopes. Proc Natl Acad Sci USA 1988; 85:8271-5.
31. 31. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991; 88:8317-21.
32. 32. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31-7.
33. 33. Stromberg A, Romanus V, Burman LG. Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J Infect Dis 1991; 164:595-8.
34. 34. Martin DR, Single LA. Molecular epidemiology of group A streptococcus M type 1 infections. J Infect Dis 1993; 167:1112-7.
35. 35. Dale JB. Group A streptococcal vaccines. Infect Dis Clin North Am 1999; 13:227-43.